1. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Issue 1 (January 2019) Authors: Jackson, Graham H; Davies, Faith E; Pawlyn, Charlotte; Cairns, David A; Striha, Alina; Collett, Corinne; Hockaday, Anna; Jones, John R; Kishore, Bhuvan; Garg, Mamta; Williams, Cathy D; Karunanithi, Kamaraj; Lindsay, Jindriska; Jenner, Matthew W; Cook, Gordon; Russell, Nigel H; Kaiser, Martin F; D... Journal: Lancet oncology Issue: Volume 20:Issue 1(2019) Page Start: 57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open‐label, randomised, Phase III trial. (12th July 2020) Authors: Jackson, Graham H.; Pawlyn, Charlotte; Cairns, David A.; Striha, Alina; Collett, Corinne; Waterhouse, Anna; Jones, John R.; Wilson, Jamie; Taylor, Craig; Kishore, Bhuvan; Garg, Mamta; Williams, Cathy D.; Karunanithi, Kamaraj; Lindsay, Jindriska; Jenner, Matthew W.; Cook, Gordon; Russell, Nigel H.... Journal: British journal of haematology Issue: Volume 192:Number 5(2021) Page Start: 853 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗